SubHero Banner

Symdeko (tezacaftor/ivacaftor and ivacaftor) – New drug approval

February 12, 2018 - Vertex announced the FDA approval of Symdeko (tezacaftor/ivacaftor and ivacaftor) for the treatment of patients with cystic fibrosis (CF) aged 12 years and older who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence.

Download PDF